Most specialty drug companies obtain product rights only for one or two national markets and so cannot fund clinical development and sales expansion by sub-licensing or partnering; they must sell equity to finance 100% of development & marketing costs, resulting in highly ..... founders and lower returns for all their investors. (*) depressed (*) diluted (*) disillusioned (*) distraught
This is a companion discussion topic for the original entry at https://english.best/questions/8848,most-specialty-drug-companies-obtain-product-rights-only-for-one-or-two-national-markets-and-so-cannot-fund-clinical-development-and-sales-expansion-by-sub-licensing-or-partnering-they-must-sell-equity-to-finance-100-of-development-marketing-costs-resulting-in-highly-___-founders-and-lower-returns-for-all-their-investors/